The chorionic gonadotropin titer now makes it possible to identify early those postmolar patients who are likely to progress to choriocarcinoma, thereby opening the way to definitive treatment of this highly lethal condition. Complete and sustained remission can now be achieved in 90% of patients in whom appropriate chemotherapy is begun within four months of disease onset, and in 75% of all treated cases.